#AACRBlog
The opening keynotes at last month’s #AACRdisp26 by Monica Baskin of VCU and patient advocate @michaelhhu.bsky.social explored actionable solutions to address cancer disparities and gaps in care for stage 4 patients. Learn more on the #AACRBlog: buff.ly/ClhNvdl
November 17, 2026 at 10:30 PM
About 5% of non-small cell lung cancer are ALK positive. Michael Hu recently shared his story as a patient with stage 4 ALK-positive lung cancer at the AACR Conference on the Science of Cancer Health Disparities. Learn more on the #AACRBlog: buff.ly/83zTbBx
Cancer Health Disparities: Actionable Solutions, Gaps in Stage 4 Care, and Honoring Sanya Springfield
Examples of solutions for addressing cancer health disparities and remaining gaps in care for stage 4 patients were discussed at an AACR conference.
buff.ly
November 17, 2026 at 8:51 PM
Enfortumab vedotin-ejfv is an antibody-drug conjugate, which is a type of targeted therapy. Learn more about how antibody-drug conjugates work on the #AACRBlog: buff.ly/8kMrAm5
What Are Antibody-drug Conjugates?
Learn about what antibody-drug conjugates (ADCs) are, including how they work and what cancers these therapies are approved to treat.
buff.ly
November 13, 2026 at 8:17 PM
Before @aacrjournals.bsky.social published Cancer Research, there was The American Journal of Cancer, which published AACR’s first Chinese-authored study more than 90 years ago. Learn more about AACR’s collaborative history with China on the #AACRBlog: buff.ly/RXJwaRu
November 11, 2026 at 2:01 AM
Opportunities to accelerate cancer drug development and make it more efficient while broadening patient access were key points explored at the AACR-Industry Roundtable 2026. Read more on the #AACRBlog: buff.ly/g4SE6rV
November 6, 2026 at 10:30 PM
The recent AACR Grantee Summit showcased the impactful research made possible through AACR funding and reinforced a powerful message: innovation thrives through collaboration. Learn more on the #AACRBlog: buff.ly/NvTEzCV #AACRGrants
November 4, 2026 at 10:15 PM
Vanessa Hayes, who published the first complete African human genome in 2010, spoke at #AACRdisp26 about how her work is uncovering potential genetic and environmental factors driving disparities in prostate cancer. Learn more on the #AACRBlog: buff.ly/s0BNuym @sydney.edu.au
November 5, 2026 at 2:01 AM
How might living in an ethnic enclave impact cancer risk and outcomes? Learn more on the #AACRBlog in an article from Cancer Today magazine: buff.ly/gh3heaF #AACRdisp26
November 2, 2026 at 1:01 AM
Researchers are uncovering a complex dialogue between tumor cells and nerves that may help drive the growth and spread of pancreatic cancer. Learn more about this research, which was presented at #AACRpan26, on the #AACRBlog: buff.ly/8C93IuV
October 29, 2026 at 1:01 AM
From innovative CAR T-cell approaches to new insights into tumor-infiltrating lymphocytes as an immunotherapy biomarker in triple-negative breast cancer, the Editors’ Picks for October showcase some of the latest advances in cancer research. Learn more on the #AACRBlog: buff.ly/jB8hthD
October 28, 2026 at 2:00 AM
A new cancer vaccine has delivered positive results for patients with high-risk melanoma, significantly reducing the risk of recurrence. Read about the science behind the treatment and the latest phase III results on the #AACRBlog: buff.ly/QPPnu8i
October 27, 2026 at 12:00 AM
This year's Frontiers in Cancer Science conference in Singapore will be held November 11-13. The conference cochairs Gopal Iyer, MBBS (Hons), PhD, and Choon Kiat Ong, PhD, shared what attendees can expect from the scientific and education sessions on the #AACRBlog: buff.ly/nYcMzNp
October 24, 2026 at 9:01 PM
The breakthrough discovery of RAS-targeted therapies was built on decades of research supported by the NCI. Read the #AACRBlog for more details. #FundNIH
October 22, 2026 at 1:01 AM
At #AACRpan26, Fellow of the AACR Academy Kevan Shokat, PhD, received the Stephenson Global Prize from the Stephenson Global Pancreatic Cancer Research Institute for his groundbreaking work targeting the once undruggable KRAS. Learn more on the #AACRBlog: buff.ly/eeohZxt #AACRFellows
October 22, 2026 at 1:01 AM
Updated survey results reveal the impact of federal policy changes on cancer disparities researchers, while a session at #AACRdisp26 highlighted the progress that has been made in this field. Learn more on the #AACRBlog: buff.ly/2EJYqDT #CancerDisparitiesReport
October 21, 2026 at 7:32 PM
Dostarlimab is an immune checkpoint inhibitor. Learn more about this and other forms immunotherapy on the #AACRBlog: buff.ly/khKfu10
What Is Immunotherapy?
What Is immunotherapy? Learn about types of cancer immunotherapy, including immune checkpoint inhibitors, adoptive cell therapy, therapeutic vaccines, and more.
buff.ly
October 19, 2026 at 7:51 PM
The recent diagnosis of Pope Leo XIV has lung cancer in the news again. Lung cancer is a serious disease, but due to decades of cancer research, the outcomes for patients have continued to improve. Learn more on the #AACRBlog: buff.ly/bNooca2
October 19, 2026 at 12:00 AM
On October 25, the Friends of the AACR Foundation will recognize Domenick Bucci, MD, as its Humanitarian Honoree and the HEADstrong Foundation as its Community Impact Award recipient at the annual Party with a Purpose. Learn more on the #AACRBlog: buff.ly/ETG4de7
October 15, 2026 at 1:00 AM
Learn about other developments in treating BCG-resistant NMIBC on the #AACRBlog: buff.ly/5jkzeJY
Bladder Cancer: Burgeoning Beyond BCG
At a recent AACR Special Conference, experts discussed emerging therapeutic options to overcome resistance to Bacillus Calmette-Guérin (BCG).
buff.ly
October 14, 2026 at 7:55 PM
The latest issue of Cancer Today features articles on activity-based groups for cancer survivors, new treatment options for multiple myeloma, a drug that can boost chemotherapy’s effectiveness, and more. Read about the issue on the #AACRBlog: buff.ly/w8A603Y
October 10, 2026 at 9:01 PM
Patients with cancer who exercise have been found to have a lower risk of death, reduced risk of recurrence for some cancers, and improved quality of life. Learn more about exercise's benefits for patients on the #AACRBlog: buff.ly/1voCNXq
What Are the Benefits of Exercise for Cancer Patients?
Several new studies show how exercise can extend cancer patients’ survival, reduce the risk of recurrence, and improve quality of life.
buff.ly
October 8, 2026 at 2:15 PM
This approval was based on results from the HER2CLIMB-05 trial, which were presented at the San Antonio Breast Cancer Symposium 2025. Learn more about this trial and the history of tucatinib as a treatment for breast cancer on the AACRBlog: buff.ly/LURJt1a
Tracking the History of Tucatinib for Breast Cancer Treatment at SABCS
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
buff.ly
October 7, 2026 at 6:07 PM
The FDA expanded treatment options for cancers of the breast, lung, pancreas, and more during the third quarter of 2026. Learn how these new approvals fit into the therapeutic landscape on the #AACRBlog: buff.ly/mY5QpZ3
October 5, 2026 at 10:00 PM
The AACR Special Conference on Pediatric Cancer kicked off with talks from Charles Mullighan and Nicole Michmerhuizen, who discussed how genomics reveals novel biological insights into pediatric leukemia. Learn more on the #AACRBlog: buff.ly/VRibpBw #AACRpediatric26
Genomics Reveal New Layers of Pediatric Leukemia Biology
At the AACR Special Conference on Pediatric Cancer, Charles Mullighan and Nicole Michmerhuizen spoke about pediatric leukemia research.
buff.ly
October 1, 2026 at 12:01 AM
AACR and Kids Beating Cancer announced a new grant at the AACR Special Conference on Pediatric Cancer that will fund researchers who are studying pediatric leukemia. Read more about this new collaboration and the grant on the #AACRBlog: buff.ly/Kp7EVE4 #AACRpediatric26
AACR and Kids Beating Cancer Launch New Grant to Advance Pediatric Leukemia Research
AACR and Kids Beating Cancer launched a new grant to support research aimed at improving outcomes for children with high-risk leukemia.
buff.ly
September 28, 2026 at 10:01 PM